AR012702A1 - Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente - Google Patents

Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente

Info

Publication number
AR012702A1
AR012702A1 ARP980102250A ARP980102250A AR012702A1 AR 012702 A1 AR012702 A1 AR 012702A1 AR P980102250 A ARP980102250 A AR P980102250A AR P980102250 A ARP980102250 A AR P980102250A AR 012702 A1 AR012702 A1 AR 012702A1
Authority
AR
Argentina
Prior art keywords
combination
purin
methanol
amino
patient
Prior art date
Application number
ARP980102250A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709945.1A external-priority patent/GB9709945D0/en
Priority claimed from GBGB9719883.2A external-priority patent/GB9719883D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR012702A1 publication Critical patent/AR012702A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP980102250A 1997-05-17 1998-05-14 Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente AR012702A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt
GBGB9719883.2A GB9719883D0 (en) 1997-09-19 1997-09-19 Antiviral combinations

Publications (1)

Publication Number Publication Date
AR012702A1 true AR012702A1 (es) 2000-11-08

Family

ID=26311543

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102250A AR012702A1 (es) 1997-05-17 1998-05-14 Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente

Country Status (12)

Country Link
EP (1) EP0979082A1 (fr)
JP (1) JP2001525839A (fr)
AR (1) AR012702A1 (fr)
AU (1) AU7912398A (fr)
BR (1) BR9809127A (fr)
CA (1) CA2289655A1 (fr)
CO (1) CO4950569A1 (fr)
HR (1) HRP980264A2 (fr)
MA (1) MA26496A1 (fr)
NO (1) NO995620L (fr)
PE (1) PE74799A1 (fr)
WO (1) WO1998052570A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990030A2 (en) * 1998-02-17 1999-10-31 Michael B. Maurin Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
EP1332757B1 (fr) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Formulation de comprimé d' efavirenz
PE20000559A1 (es) * 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
WO2013111147A1 (fr) * 2011-12-19 2013-08-01 Hetero Research Foundation Compositions à libération prolongée de névirapine
US9457028B2 (en) 2013-02-27 2016-10-04 Kyoto University Pharmaceutical composition for use in prevention or treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc

Also Published As

Publication number Publication date
MA26496A1 (fr) 2004-12-20
CO4950569A1 (es) 2000-09-01
WO1998052570A1 (fr) 1998-11-26
HRP980264A2 (en) 1999-02-28
BR9809127A (pt) 2000-08-01
EP0979082A1 (fr) 2000-02-16
PE74799A1 (es) 1999-08-13
CA2289655A1 (fr) 1998-11-26
JP2001525839A (ja) 2001-12-11
NO995620D0 (no) 1999-11-16
AU7912398A (en) 1998-12-11
NO995620L (no) 2000-01-14

Similar Documents

Publication Publication Date Title
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
ES2145913T3 (es) Inhibidores de metaloproteasas.
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
BR9406893A (pt) Emprego de nona- e decapeptideos para a preparação de um medicamento para o combate da aids
RU94026283A (ru) Фармацевтическое соединение
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
AR003440A1 (es) Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados.
AR012294A1 (es) Derivados de sulfonamida, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen, uso de dichos derivados para lapreparacion de un medicamento.
PT914110E (pt) Metodo de modulacao da micro-circulacao
AR031117A1 (es) Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica
DE69718734D1 (de) Bicyclische aromatische verbindungen
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
HUP0001632A2 (hu) Szelektív foszfodiészteráz PDE enzim inhibitort tartalmazó gyógyszerkészítmények
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
MX9308005A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
AR012702A1 (es) Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente
MXPA03010679A (es) Una composicion para acelerar la cicatrizacion de fractura osea.
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
BR0206954A (pt) Processo de terapia para câncer
ITMI932189A1 (it) Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta
MX9306607A (es) Dindihidrogeno-otorfosfato de tilidina, procedimiento para su obtencion y las preparaciones farmaceuticas que lo contienen.
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso
RU2005131578A (ru) Аплидин для лечения множественной миеломы
AR002957A1 (es) Una combinacion de compuestos utiles, su uso para preparar un medicamento, y una composicion y combinacion farmaceutica que los contienen.
AR036009A1 (es) Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica